The expiry of Humira ® market exclusivity and the entry of adalimumab biosimilars in Europe: An overview of pricing and national policy measures
Conclusion: Even though originator adalimumab is the highest selling product in the world, few countries have implemented specific policies and practices for (biosimilar) adalimumab. Countries with biosimilars on the market seem to have competition lowering list or actual prices. Reported discounts varied widely between countries.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Denmark Health | Drugs & Pharmacology | Humira | Italy Health | Netherlands Health | Norway Health | Poland Health | Romania Health | Scotland Health